Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is a promising investment opportunity as they have a strong and comprehensive drug development pipeline, including a potential multi-billion dollar revenue generator in tinlarebant for the treatment of degenerative retinal diseases like GA and STGD1. With a comfortable cash position and key commercialization preparations underway, they are well poised for success with a potential FDA approval in 2026 for tinlarebant as the first ever FDA-approved therapy for STGD1. The completion of their rolling NDA submission in 2Q26 highlights their commitment to bringing this important treatment to market.

Bears say

Belite Bio is a clinical stage biopharmaceutical company with a drug development pipeline that includes tinlarebant for the treatment of degenerative retinal diseases and LBS-009 for metabolic diseases. While tinlarebant has a potential multi-billion dollar market opportunity in both Stargardt disease and geographic atrophy associated with dry age-related macular degeneration, there are risks including potential failure in clinical trials and failure to achieve commercial success. The company's current valuation is based on a discounted cash flow analysis and assigned probabilities of approval for their drug candidates. Management plans to conduct an interim analysis in late 2026, and the company may use safety data from the Phase 3 PHOENIX trial to support a potential NDA for Stargardt disease.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.